Numbers

The Numbers

IFF trades at roughly $70 a share, or about 1.2x book value — the lowest multiple this stock has seen in more than a decade — because a business that historically compounded at 19% operating margins and low-teens ROIC is now running at negative GAAP operating profit, net debt above 10x EBITDA, and FY2025 free cash flow of only $256M against $8.3B of goodwill still on the balance sheet. The single metric most likely to rerate or derate the equity is the operating-margin trajectory in the reshaped four-segment portfolio (Taste, Food Ingredients, Health & Biosciences, Scent) now that the Pharma Solutions and Nitrocellulose businesses are gone and debt paydown is the stated priority. Everything below is built to show whether the cash engine and balance sheet are healing fast enough to justify the 1.2x book price.

Snapshot

1. What is this company economically?

IFF is a specialty-ingredients business — Taste, Food Ingredients, Health & Biosciences and Scent — selling into food, beverage, personal care and home care formulators. Revenue scale stepped up from ~$5B in 2020 to ~$11.5B in 2021 following the Nutrition & Biosciences (N&B) merger with DuPont, and has since drifted back toward $10.9B as the company divests non-core units. The business is capital-light at the operating level (capex ~5% of revenue) but balance-sheet heavy — goodwill and intangibles together still account for 56% of total assets.

Revenue and operating income — long horizon

The margin chart is the single most important picture in this report. IFF ran a 17–19% operating-margin business through the 2010s. Post-N&B the economics changed: a bigger, more commoditized, more goodwill-laden enterprise has oscillated between 5% and -18% GAAP operating margin ever since. 2024's rebound to 6.7% was the first sign of a floor; 2025 slipped back below zero because of divestiture-related charges.

Revenue mix — the new four-segment IFF

Food Ingredients is now the largest segment, followed by Taste and Scent at roughly equal scale, then Health & Biosciences. Pharma Solutions — 3.4% of 2025 revenue and sold during the year — is the discontinued remnant.

2. Is it healthy and durable?

Quality scorecard

Binder Error: Could not ORDER BY column "CASE  WHEN ((flag = 'Red')) THEN (1) WHEN ((flag = 'Yellow')) THEN (2) ELSE 3 END": add the expression/function to every SELECT, or move the UNION into a FROM clause.

Five of nine quality signals flash red. The balance sheet is the central concern: 10x net-debt-to-EBITDA exists because the denominator is compressed by charges, not because the numerator is catastrophic. Reported total debt actually fell from $10.1B at end-2023 to $6.0B at end-2025 — a $4B reduction funded by divestiture proceeds and FCF.

Balance-sheet health — debt and goodwill over time

The 2021 step-change is the N&B merger: debt and goodwill both exploded. What happened next is the important part — debt has come down from $11.4B to $6.0B in four years, while goodwill has been written down from $16.4B to $8.3B via impairment charges. Equity is roughly flat because losses and impairments offset each other. This is a deleveraging story in progress, not one that is done.

3. Cash generation — the real earnings

Cash conversion tells the story GAAP earnings don't. Even when net income was deeply negative in 2022–2023 because of goodwill impairments (non-cash), operating cash flow stayed positive — $397M and $1,455M respectively. FCF over the last five years totals about $2.75B despite cumulative reported GAAP losses of $4.3B. That gap is goodwill and intangibles amortization washing through non-cash charges — a hallmark of an M&A-built balance sheet, not a broken operating business.

The concern is the trend: FCF has compressed from $1.04B in 2021 to $952M (2023) to $607M (2024) to $256M (2025). Capex has risen from $393M to $594M over the same stretch — the business is investing more per dollar of sales than it did pre-merger.

Capital allocation — last 10 years

From "M&A-heavy with modest dividends" (2018: $4.86B in acquisitions including Frutarom) the posture has flipped completely to "debt paydown plus a trimmed dividend." In 2025 IFF paid down $2.91B of long-term debt — the largest single line of capital allocation by a wide margin. Share buybacks are token. The dividend was cut in 2024 (from $4.05 per share in 2022 to roughly $1.60 in 2025). That cut is the clearest management signal that cash flexibility, not shareholder return, is the near-term priority.

4. What does the market think?

Valuation — now vs own history

IFF used to be a 4–6x book, 20x earnings business — a premium-specialty chemicals multiple. Since the 2018 Frutarom deal and even more so since the 2021 N&B merger, P/B has compressed to 1.2x — below even deep-value chemicals peers. P/E has been meaningless for four of the last five years because GAAP earnings are negative or barely positive. EV/EBITDA at 40x today is misleading for the same reason — the denominator is compressed. On cleaner adjusted-EBITDA assumptions (roughly $1.9B run-rate), EV/EBITDA is closer to 12–13x, closer to the historical median.

The 1.2x P/B is the cleanest number for assessing the margin of safety. Assuming the $8.3B of goodwill on the books is worth at least half of what it cost, the equity is trading roughly at tangible-book-plus-a-small-goodwill-haircut.

Peer comparison

Fair value scenarios

Close

What the numbers confirm. The bull thesis on the operating business has merit — cash flow stayed positive through two years of massive goodwill impairments, FCF has been consistently positive in nine of the last ten years, and $5B of debt has been paid down in three years. The N&B deal was a destructive act of capital allocation; the operating business underneath is still a durable specialty-ingredients franchise.

What the numbers contradict. The "IFF is a falling knife" narrative is stale. Reported GAAP losses are largely non-cash. Debt is falling fast, not rising. And the stock is trading at 1.2x book — its lowest multiple in 15+ years — at a moment when management has finally stopped making acquisitions and started paying down debt with both hands. The popular view that this is a broken story understates how much has already been fixed.

What to watch next year. Three numbers. First, adjusted operating EBITDA margin in the four-segment portfolio (2025 baseline ~15%, management target 17–18%). Second, net debt / EBITDA, which needs to travel from 10x reported / ~3.5x adjusted down toward management's 3x target — debt maturities in 2026–2027 and pace of FCF deployment are the mechanics. Third, FCF run-rate — 2025's $256M is the worst year outside the 2022 dip; a return to the $600M–$1B range is required to validate base-case fair value.